You have accessJournal of UrologyProstate Cancer: Localized VII1 Apr 2014MP62-07 A COMPETING RISK ANALYSIS OF CANCER-SPECIFIC MORTALITY OF INITIAL TREATMENT WITH RADICAL PROSTATECTOMY VERSUS RADIATION THERAPY IN HIGH-RISK PROSTATE CANCER Joo Yong Lee, Jae Hyeok Choi, In Kyoung Kim, Hae Do Jung, Ho Won Kang, Young Eun Yoon, Ji Yong Ha, Kang Su Cho, Joong Shik Lee, In Rae Cho, and Young Deuk Choi Joo Yong LeeJoo Yong Lee More articles by this author , Jae Hyeok ChoiJae Hyeok Choi More articles by this author , In Kyoung KimIn Kyoung Kim More articles by this author , Hae Do JungHae Do Jung More articles by this author , Ho Won KangHo Won Kang More articles by this author , Young Eun YoonYoung Eun Yoon More articles by this author , Ji Yong HaJi Yong Ha More articles by this author , Kang Su ChoKang Su Cho More articles by this author , Joong Shik LeeJoong Shik Lee More articles by this author , In Rae ChoIn Rae Cho More articles by this author , and Young Deuk ChoiYoung Deuk Choi More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2014.02.1964AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES There is no consensus on the optimal treatment for localized high-risk prostate (PCa), and much debate exists regarding the ideal treatment approach. We conducted to evaluate the competing risks of prostate cancer-specific mortality after initial therapy with radical prostatectomy (RP) versus combined-modality treatment (CMT) with radiotherapy (RT) in men with localized high-risk PCa. METHODS We reviewed 4,301 men treated with RP and RT combined with androgen-deprivation therapy between April 1990 and December 2011 at a single institution. High-risk PCa is defined by clinical stage ≥T2c, serum PSA >20 ng/ml, or biopsy Gleason sum of 8–10. A single surgeon performed initial RT (n=135) or RP (n=545) on men with localized high-risk PCa. Competing risk analysis assessed the association of RP or RT with cancer-specific mortality, and overall mortality. Secondary analysis with propensity score-matching further elucidated patient characteristics (Fig. 1). RESULTS During a median follow-up 41 months, 37 (5.4%) men with high-risk PCa died due to PCa (23 in RT group; 14 in RP group). The 5-year estimates of PCa-specific mortality rate for men treated with RP and RT were 3.2% and 10.6%, respectively. Cumulative incidence estimates for PCa-specific mortality were statistically increased amongst men treated with RT (P=0.001). Propensity score-matching extracted 122 men with high-risk PCa from the total patient cohort. Cumulative incidence estimates for PCa-specific mortality were statistically different amongst men treated with RT (P=0.027) (Fig 2). CONCLUSIONS Initial treatment with RP versus RT was associated with a decreased risk of cancer-specific mortality in men with localized high-risk PCa. © 2014FiguresReferencesRelatedDetails Volume 191Issue 4SApril 2014Page: e719-e720 Advertisement Copyright & Permissions© 2014MetricsAuthor Information Joo Yong Lee More articles by this author Jae Hyeok Choi More articles by this author In Kyoung Kim More articles by this author Hae Do Jung More articles by this author Ho Won Kang More articles by this author Young Eun Yoon More articles by this author Ji Yong Ha More articles by this author Kang Su Cho More articles by this author Joong Shik Lee More articles by this author In Rae Cho More articles by this author Young Deuk Choi More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...